Alvogen, a privately owned pharmaceutical company headquartered in the US, was founded in 2009 and employs approximately 570 individuals. The company focuses on developing, manufacturing, and selling generic, brand, over-the-counter brands, and biosimilar products for patients around the world.
On April 9, 2026, Lotus Pharmaceutical Co. Ltd. reported unaudited consolidated revenues for March 2026 of NT$4,354 million, representing a 174% year-over-year increase, primarily driven by the consolidation of Alvogen and strong growth in its B2B business. Previously, on February 23, 2026, Alvogen, a US-based wholly owned subsidiary of Lotus Pharmaceutical, entered into a global license agreement with Solaxa Inc. for the development and commercialization of SLX-100. This agreement covers SLX-100 for spinocerebellar ataxia type 27B (SCA27B) across global markets.
Subscribe for full access to Alvogen's products in full detail 
